Condition (MeSH)
Candidiasis, Oral
ClinicalTrials.gov lists 48 trials for Candidiasis, Oral or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
48 of the 48 trials are tagged with Candidiasis, Oral itself; the rest are tagged with a narrower condition beneath it.
When did Candidiasis, Oral trials start? (24)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 2 |
| 2024 | 3 |
| 2023 | 2 |
| 2021 | 1 |
| 2020 | 1 |
| 2019 | 1 |
| 2017 | 2 |
| 2016 | 3 |
| 2012 | 1 |
Showing 10 of 24 earlier years.
No forecast is made for this condition: it averages 1.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 48 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Candidiasis, Oral trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 4 |
| Phase 1/2 | 1 |
| Phase 2 | 6 |
| Phase 3 | 7 |
| Phase 4 | 4 |
| Not applicable | 20 |
| Observational | 6 |
How many Candidiasis, Oral trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 2 |
| Recruiting | 2 |
| Completed | 39 |
| Terminated | 1 |
| Unknown status | 4 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Candidiasis, Oral trials? (10)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Bristol-Myers Squibb | 3 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 3 |
| Pfizer | 3 |
| Astellas Pharma Inc | 2 |
| Janssen, LP | 2 |
Showing 5 of 10 sponsors.
Which drugs are being tested for Candidiasis, Oral? (4)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Nystatin | 5 |
| Itraconazole | 2 |
| Miconazole | 2 |
| AMPHOTERICIN B | 2 |
Interventions as named in the registry (11)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Fluconazol | 8 |
| MK0991, caspofungin acetate | 2 |
| Comparator: Micafungin sodium | 2 |
| Posaconazole PFS | 2 |
| Vacucis autovaccine | 1 |
Showing 5 of 11 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Candidiasis, Oral? (94)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials. | The British journal of dermatology | 2024 | Yes |
| The anti-fungal effect of miconazole and miconazole-loaded chitosan nanoparticles gels in diabetic patients with Oral candidiasis-randomized control clinical trial and microbiological analysis. | BMC oral health | 2024 | Yes |
| Identification and susceptibility testing of oral candidiasis in advanced cancer patients. | BMC oral health | 2023 | Yes |
| Treatment for recurrent vulvovaginal candidiasis (thrush). | The Cochrane database of systematic reviews | 2022 | Yes |
| Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension Study. | Arthritis & rheumatology (Hoboken, N.J.) | 2022 | Yes |
Showing 5 of 94 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.